These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28244816)

  • 1. Vaccine nanoparticles for protection against HIV infection.
    Aikins ME; Bazzill J; Moon JJ
    Nanomedicine (Lond); 2017 Mar; 12(6):673-682. PubMed ID: 28244816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New concepts in HIV-1 vaccine development.
    Stephenson KE; D'Couto HT; Barouch DH
    Curr Opin Immunol; 2016 Aug; 41():39-46. PubMed ID: 27268856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospects for a globally effective HIV-1 vaccine.
    Excler JL; Robb ML; Kim JH
    Vaccine; 2015 Nov; 33 Suppl 4():D4-12. PubMed ID: 26100921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.
    Haut LH; Ertl HC
    J Leukoc Biol; 2009 Oct; 86(4):779-93. PubMed ID: 19597003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges in the development of an HIV-1 vaccine.
    Barouch DH
    Nature; 2008 Oct; 455(7213):613-9. PubMed ID: 18833271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV vaccine: hopes and hurdles.
    Chhatbar C; Mishra R; Kumar A; Singh SK
    Drug Discov Today; 2011 Nov; 16(21-22):948-56. PubMed ID: 21889604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future paths for HIV vaccine research: Exploiting results from recent clinical trials and current scientific advances.
    Bansal GP; Malaspina A; Flores J
    Curr Opin Mol Ther; 2010 Feb; 12(1):39-46. PubMed ID: 20140815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief history of the global effort to develop a preventive HIV vaccine.
    Esparza J
    Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV Vaccine Efficacy Trials: RV144 and Beyond.
    Heger E; Schuetz A; Vasan S
    Adv Exp Med Biol; 2018; 1075():3-30. PubMed ID: 30030787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A shot at AIDS.
    Koff WC
    Curr Opin Biotechnol; 2016 Dec; 42():147-151. PubMed ID: 27153215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for vaccine protection against HIV-1 infection and AIDS.
    Letvin NL; Barouch DH; Montefiori DC
    Annu Rev Immunol; 2002; 20():73-99. PubMed ID: 11861598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for AIDS vaccines.
    Stott EJ; Schild GC
    J Antimicrob Chemother; 1996 May; 37 Suppl B():185-98. PubMed ID: 8818840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of HIV vaccine candidates for concurrent testing in an efficacy trial.
    Huang Y; DiazGranados C; Janes H; Huang Y; deCamp AC; Metch B; Grant S; Sanchez B; Phogat S; Koutsoukos M; Kanesa-Thasan N; Bourguignon P; Collard A; Buchbinder S; Tomaras GD; McElrath J; Gray G; Kublin JG; Corey L; Gilbert PB
    Curr Opin Virol; 2016 Apr; 17():57-65. PubMed ID: 26827165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.
    O'Connell RJ; Kim JH; Excler JL
    Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved outlook on HIV-1 prevention and vaccine development.
    Vasan S; Michael NL
    Expert Opin Biol Ther; 2012 Aug; 12(8):983-94. PubMed ID: 22583109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systems biology and the quest for correlates of protection to guide the development of an HIV vaccine.
    Kuri-Cervantes L; Fourati S; Canderan G; Sekaly RP
    Curr Opin Immunol; 2016 Aug; 41():91-97. PubMed ID: 27392184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.